Timing and Relationship: The Key to Compelling Investor Mandates

8 Apr

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the LSN Partnering Conference Series

As the life science arena shifts, so do investment and licensing mandates and the technologies that investors and strategic partners seek. Life Science Nation (LSN) is known for its curated partnering database for fundraising early-stage companies across the silos of drugs, devices, diagnostics and digital health. This database has ten categories of investors ranging from angel groups and family offices to VCs, PEs, Big Pharma/Medtech, foundations and the non-dilutive federal, state and regional agencies.

The LSN mantra to healthcare scientist-entrepreneurs and fundraising CEOs is that partnering is a numbers game, and that getting a Global Target List (GTL) of potential partners that are a fit for your stage of development and product set is a crucial step to a successful fundraising campaign. Furthermore, it’s essential to canvass outside your region, engaging global partners to maximize the likelihood of building a relationship that could secure a partnership. 

The LSN Investor Research Team curates the LSN Investor Database, which consists of profiles that fundraising clients can access with an annual subscription. Tools like the database are essential aids for success in a global fundraising campaign. The database features more than ten thousand investor contacts representing several thousand funding and licensing firms. The team’s goal is to keep all the partnering mandates updated in order to ensure the best fit, and this is done through bi-annual interviews. 

These firms are willing to be part of the LSN Investor Platform because we provide them with quality deal-flow, companies that know they are a fit for the firm’s investment theme or partnering interests. Additionally, each year, five Redefining Ealy Stage Investments (RESI) partnering events attract the who’s-who of early-stage life science investing and give them another avenue to connect with fundraising companies that match their interests. These conferences consist of investor panels, workshops, and matched partnering meetings, taking advantage of the profiles the investor research team gathers and the long-term relationships we build while keeping their mandates current.  

The relationship between LSN and the global investor community is deep and has helped hundreds of companies get funded by connecting with investors and partners. Just this week, the Investor Research Team has updated over forty-five mandates, facilitating super fresh profile updates for LSN clients seeking funding. Check out this week’s investor mandates and reach out to your LSN business development representative to view these investors and learn how to get plugged into the LSN partnering ecosystem.

Want to learn more? The business development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International & MA (USA) West Coast (USA) East Coast (USA) Midwest (USA) & Canada 
Greg Mannix
Vice President International Business Development
Schedule a call with me!
Candice He
Director of Pacific Region & Global Investment Strategist
Schedule a call with me!
Ashley Zborowski
Director of Business Development
Schedule a call with me!
Elizabeth Murphy
Manager of Business Development
Schedule a call with me!

Starting with Pep: An Early-Stage Conversation with Creative Bio-Peptides

8 Apr

By Rory McCann, Marketing Manager & Conference Producer, LSN

Creative Bio-Peptides is an early-stage company, founded and led by Dr. Michael Ruff, with a mission to improve lives through developing oral receptor-active peptides targeting neurodegenerative diseases. We spoke with Chief Business Officer, Michael Simon about the early-stage journey of Creative Bio-Peptides – how it was started, what their strategy looks like today, and where they see the company going forward.

Creative Bio-Peptides is a past participant at an Redefining Early Stage Investments (RESI) partnering event. Learn more about RESI and sign up by April 9 to save $100 on super early bird rates.

Digital RESI June Super Early Bird Ends Tomorrow

8 Apr

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN


Digital Redefining Early Stage Investments (RESI), June 8-10, is around the corner, which means that super early bird rates end tomorrow! Sign up by Friday, April 9 to save $100 on registration to take advantage of the RESI partnering system which enables early-stage fundraising executives to source investors and strategic partners based on a fit for their product and stage of development.

Digital RESI June also offers a variety of investor panels, educational workshops, and the Innovator’s Pitch Challenge – all designed to offer valuable insight to entrepreneurs and opportunities to make matches, build relationships, and cut deals. Digital RESI has been a part of hundreds of companies’ early-stage fundraising success stories. Sign up to save and make it a part of yours!

Hot Investor Mandate: USA-Based Family Office Invests in Early-Stage Companies Across the Globe, With Strong Interest in Therapeutics Opportunities

8 Apr

A family office based in the USA has several decades of experience in investing in life science companies and taking them public. The firm participates in deals across all stages of development, from seed to mezzanine funding. In early-stage deals, the firm’s initial check size is usually between $250-500K, with potential for follow-on financing as the companies achieve key growth milestones. The firm is actively involved with a well-established angel investor group and makes investments through this group as well. The firm is open to opportunities all across the globe.

The firm seeks to invest broadly across different silos of the life sciences ecosystem, from therapeutics, devices, diagnostics, and digital health. The firm’s strongest interest and expertise lies in biotech, and many of the firm’s investments have been in therapeutics companies. The firm is also open to companies of all stages of development and is indication agnostic, but has significantly higher standards for oversaturated, competitive spaces such as oncology.

The firm has no explicitly stated company or management team requirements. The firm likes to become actively involved in their portfolio companies and supports them with needed resources and advisory services to help them grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia Cross Border VC Firm Invests in Therapeutics, Devices, and Diagnostics, Open to USA & China-Based Companies

8 Apr

A venture capital firm headquartered in Taiwan currently manages a fund focuses 50% on bio & healthcare-related investments, and outside of life sciences the firm invests in all types of high potential technologies with disruptive potential. The firm primarily seeks investment opportunities in USA, China and Taiwan.

The firm is most interested in novel therapeutics, but also invests in medical devices and diagnostics. Within therapeutics, the firm has invested across various modalities, from traditional small molecule therapeutics to emerging therapies like immunotherapy and cell/gene therapy. The firm is open to pre-IND, early-stage opportunities given they have a valid proof of concept and address an area of unmet medical need. As for medical devices, the firm generally invests in 510k products and open to all types of devices that address unmet medical need.

The firm has no specific company or management team requirements. Though the firm is based in Taiwan, the firm does not require any sort of Taiwan angle or market potential when evaluating cross-border opportunities. The firm is open to leading and co-investing in investment rounds and will most likely seek board representation when acting as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe VC Firm Invests Up to €20M in Early-Stage & Growth Stage Life Science Companies Over Company Life Cycle

8 Apr

A leading Venture Capital firm investing in early-and growth stage life science companies has multiple offices in Western Europe. The firm is focused on investing in the most promising life science companies in the fields of biotechnology, therapeutics, medical technology, diagnostics and digital health. With funds totaling EUR 1.0 billion, and more than EUR 430 million committed to life sciences, the firm has been actively supporting world class private companies translating true innovation into successful businesses with exceptional growth. To date, the firm has invested in over 50 innovative life science companies. Initial ticket size ranges between EUR 5-10 million and up to EUR 20 million over the life of the investment.

The firm invests mainly in Europe and selectively in US across five broad areas:  Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology and R&D tools. Regarding therapeutics, the firm focuses on early-stage companies with preclinical proof of concept data or about to enter the clinic, with a preference for companies developing highly innovative technology platforms, or with early clinical data. In the other fields, the firm prefers companies with product candidates (with strong IP protection) approaching regulatory approval or companies who have already launched a first product and have some early market traction in the single million digit range.

The firm typically requests a board seat and looks for a strong and experienced management team while supporting highly talented entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Investment Firm Seeks Opportunities in Diagnostics, Digital Health, and Platform Technologies in USA & Canada

8 Apr

A private investment firm is looking to make venture investments in emerging fast growth projects. Typical equity investments range from $500,000 to $3 million per deal. The firm will invest in companies across the United States and Canada.

Currently the firm is most interested in areas of personal medicine diagnostics, particularly in genomics and proteomics. Other areas of high interest include, digital health, platform technologies, nutrition, clean environment, and much more selectively drug development and medical devices. The firm has experience in immunology and is more familiar with vaccine and antibody based technologies. The firm is open in terms of indication and considers orphan indications as well but requires strong data and a clear pathway to exit.

The firm invests in privately held companies and will both lead or co-invest. The firm looks to take a board seat in some of its portfolio companies though it is not a requirement. The firm looks for smart and passionate management teams with high levels of experience in the field.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: